Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9592656 | 0.87 | MAPT (0.60) | MAPTRAB9ATDP1L3MBTL1KDM4E | |
| SCHEMBL9592644 | 0.87 | MAPT (0.60) | MAPTRAB9ATDP1L3MBTL1KDM4E | |
| SCHEMBL9592503 | 0.86 | MAPT (0.59) | MAPTRAB9ANPC1 | |
| SCHEMBL9592510 | 0.86 | MAPT (0.59) | MAPTRAB9ANPC1 | |
| SCHEMBL10425372 | 0.85 | MAPT (0.62) | MAPTRAB9ATDP1L3MBTL1KDM4E | |
| SCHEMBL9590586 | 0.85 | MAPT (0.57) | MAPTRAB9A | |
| SCHEMBL9590594 | 0.85 | MAPT (0.57) | MAPTRAB9A | |
| SCHEMBL927657 | 0.84 | PARP15 (0.66) | MAPTRAB9ATDP1L3MBTL1CA1 | |
| SCHEMBL1951546 | 0.83 | MAPT (1.00) | MAPTRAB9ATDP1L3MBTL1KDM4E | |
| SCHEMBL7402974 | 0.83 | GPR119 (0.64) | MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-20 | — | — | US | disclosed |
| EP-2261213-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015225-A1 | Heterocyclic compound | MC1R, MCHR1, MCHR2 | MAPT 2592/4885RAB9A 858/4885TDP1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.